object
evalu
effect
influenza
vaccin
without
heptaval
pneumococc
conjug
vaccin
respiratori
tract
infect
rti
children
random
doubleblind
placebocontrol
trial
compris
children
age
month
previou
histori
physiciandiagnos
rti
recruit
children
assign
dose
parenter
inactiv
trival
subunit
influenza
plu
heptaval
pneumococc
conjug
vaccin
influenza
plu
placebo
vaccin
control
hepat
b
viru
vaccin
plu
placebo
main
outcom
measur
febril
rti
relat
polymeras
chain
reaction
pcr
confirm
influenza
primari
care
visit
antibiot
prescript
acut
otiti
media
aom
episod
group
ci
group
compar
control
group
occurr
pcrconfirm
influenza
reduc
ci
group
ci
group
episod
aom
reduc
ci
group
ci
group
outsid
influenza
season
signific
effect
vaccin
demonstr
studi
outcom
influenza
season
influenza
vaccin
without
pneumococc
conjug
vaccin
substanti
reduc
case
confirm
influenza
aom
episod
j
pediatr
current
studi
conduct
evalu
effect
parenter
influenza
vaccin
plu
heptaval
pneumococc
conjug
vaccin
influenza
vaccin
alon
prevent
rti
preschool
children
gener
practition
gp
central
netherland
select
children
age
month
previous
diagnos
rti
regist
accord
intern
classif
primari
care
acut
otiti
media
aom
cough
fever
acut
upper
rti
includ
common
cold
pharyng
sinus
acut
tonsil
acut
laryngitistrach
acut
bronchitisbronchiol
influenza
pneumonia
pleurisypleur
effus
respiratori
infect
use
select
criterion
increas
probabl
children
rti
studi
period
exclus
criteria
verifi
use
questionnair
complet
gp
parent
includ
chronic
asthma
recurr
wheez
longer
month
treat
corticosteroid
disord
predispos
recurr
rti
syndrom
cleft
palat
clinic
signific
hypersensit
egg
children
previou
seriou
advers
reaction
vaccin
also
exclud
children
previous
receiv
influenza
pneumococc
hepat
b
viru
hbv
vaccin
condit
vaccin
alreadi
recommend
chronic
cardiac
respiratori
condit
medic
ethic
review
board
univers
medic
center
utrecht
approv
studi
protocol
parent
told
studi
gp
written
inform
consent
obtain
parent
legal
guardian
child
studi
enrol
three
cohort
children
enrol
septemb
octob
octob
octob
tabl
children
randomli
assign
block
trival
influenza
plu
heptaval
pneumococc
conjug
vaccin
tiv
plu
placebo
vaccin
control
hbv
plu
placebo
vaccin
ratio
treatment
group
assign
reveal
parent
investig
research
personnel
conduct
followup
health
care
provid
remain
blind
throughout
studi
inject
administ
nonblind
research
nurs
involv
subsequ
followup
instruct
reveal
intervent
alloc
vaccin
administ
intramuscularli
deltoid
gluteal
muscl
separ
extrem
pneumococc
placebo
vaccin
administ
right
extrem
influenza
hbv
vaccin
left
extrem
vaccin
schedul
similar
studi
arm
tabl
children
receiv
vaccin
week
apart
year
inclus
first
cohort
children
receiv
subsequ
vaccin
subsequ
year
evalu
blind
parent
last
cohort
children
ask
vaccin
thought
child
receiv
vaccin
given
end
studi
vaccin
parent
either
know
identifi
wrong
set
vaccin
end
studi
percentag
indic
success
blind
followup
clinic
outcom
particip
began
day
second
set
vaccin
continu
month
depend
year
inclus
tabl
parent
instruct
keep
daili
diari
record
clinic
sign
symptom
associ
rti
includ
gener
weaknessmalais
rhiniti
sore
throat
earach
cough
wheezingshort
breath
shiver
muscl
ach
character
sever
scale
mild
sever
parent
also
instruct
measur
child
bodi
temperatur
prefer
end
day
use
valid
electron
tympan
thermomet
provid
trial
center
parent
also
ask
record
gp
visit
due
child
rtirel
complaint
visit
gp
instruct
complet
form
includ
inform
diagnosi
possibl
antibiot
prescript
primari
studi
outcom
febril
rti
defin
fever
tympan
temperatur
least
consecut
day
accompani
aforement
sign
symptom
rti
moder
ie
sever
ie
sever
score
incid
rti
episod
record
occur
period
least
day
without
fever
rti
symptom
secondari
outcom
febril
rtirel
polymeras
chain
reaction
pcr
confirm
influenza
see
gp
visit
antibiot
prescript
physiciandiagnos
episod
aom
influenza
season
parent
instruct
contact
trial
center
evalu
influenza
child
fever
tympan
temperatur
day
accompani
least
rtiassoci
sign
symptom
sever
score
within
day
onset
fever
symptom
train
research
assist
obtain
nasopharyng
swab
viral
determin
sampl
analyz
realtim
pcr
presenc
influenza
b
virus
nasopharyng
swab
obtain
per
influenza
season
per
child
minim
discomfort
child
studi
influenza
season
defin
period
gp
visit
influenzalik
ill
per
inhabit
per
week
netherland
total
week
consecut
year
record
european
influenza
surveil
scheme
http
wwweissorg
netherland
influenza
season
peak
patient
visit
gp
influenzalik
ill
per
inhabit
almost
isol
influenza
virus
appear
close
relat
influenza
viru
variant
circul
season
deviat
somewhat
vaccin
strain
formerli
circul
strain
influenza
season
peak
gpattend
influenzalik
ill
per
inhabit
isol
influenza
virus
appear
relat
new
variant
deviat
extent
vaccin
strain
although
influenza
virus
similar
vaccin
strain
influenza
b
viru
isol
deviat
significantli
vaccin
strain
influenza
season
includ
peak
activ
gpattend
influenzalik
ill
per
inhabit
first
peak
due
mainli
influenza
b
virus
differ
significantli
vaccin
strain
second
peak
attribut
mainli
influenza
gener
match
vaccin
strain
netherland
pneumococc
conjug
vaccin
ad
nation
infant
vaccin
program
april
catchup
program
children
age
year
influenza
dutch
immun
guidelin
recommend
vaccin
children
highrisk
medic
condit
chronic
cardiac
respiratori
diseas
estim
would
need
least
studi
subject
per
studi
arm
assum
hazard
rate
primari
outcom
per
day
followup
averag
influenza
season
durat
day
achiev
power
detect
reduct
hazard
rate
take
account
potenti
loss
followup
calcul
subject
per
arm
requir
altern
also
consid
conserv
approach
estim
would
need
studi
subject
per
studi
arm
detect
similar
reduct
risk
ratio
probabl
develop
least
febril
rti
assum
probabl
outcom
control
group
power
thu
goal
enrol
children
studi
arm
analys
carri
intentiontotreat
basi
rel
risk
rr
proport
children
least
febril
rti
febril
rti
confirm
influenza
influenza
season
vaccin
group
versu
control
groupalong
confid
interv
ci
determin
use
episheet
spreadsheet
analysi
epidemiolog
data
http
membersaolcomkrothmanepisheet
xl
use
statist
packag
sa
version
sa
institut
cari
north
carolina
incid
rate
outcom
ie
number
event
per
day
influenza
season
outsid
influenza
season
model
use
poisson
regress
account
potenti
depend
observ
within
individu
offset
includ
model
account
differ
observ
time
per
individu
incid
rate
ratio
ci
base
maximum
likelihood
estim
correspond
standard
error
total
children
enrol
includ
first
cohort
second
cohort
third
cohort
tabl
baselin
characterist
similar
studi
arm
tabl
ii
total
children
complet
studi
complet
lost
followup
partial
followup
figur
gener
vaccin
well
toler
immedi
sever
advers
event
record
febril
rti
influenza
season
influenza
season
subject
group
group
least
febril
rti
episod
versu
control
group
correspond
rr
ci
ci
respect
influenza
season
togeth
total
episod
febril
rti
report
overal
incid
rate
per
childday
followup
group
group
control
group
relat
reduct
ci
group
ci
group
compar
control
group
tabl
iii
figur
correspond
need
vaccin
children
prevent
rti
episod
febril
rti
episod
occur
influenza
season
separ
children
nosethroat
swab
influenza
viru
pcr
analysi
obtain
episod
influenza
viru
type
b
identifi
total
children
includ
children
group
group
rr
ci
group
rr
ci
confirm
case
influenza
involv
aom
physician
consult
case
group
case
group
case
group
febril
rti
episod
result
primari
care
visit
result
antibiot
prescript
result
physician
diagnosi
aom
signific
differ
rate
primari
care
visit
antibiot
prescript
seen
group
control
group
tabl
iii
aom
episod
reduc
ci
group
ci
group
compar
control
group
tabl
iii
outsid
influenza
season
total
episod
febril
rti
relat
gp
visit
antibiot
prescript
physiciandiagnos
episod
aom
record
overal
differ
rate
outcom
found
among
studi
arm
tabl
iii
similar
trend
vaccin
effect
observ
data
analyz
age
random
month
vs
month
older
random
doubleblind
placebocontrol
trial
compris
children
found
influenza
vaccin
without
heptaval
pneumococc
conjug
vaccin
effect
confirm
influenza
aom
episod
influenza
season
appear
less
effect
febril
rti
episod
gener
vac
recent
metaanalys
effect
influenza
vaccin
healthi
children
age
report
reduct
ci
ci
ci
confirm
influenza
parenter
inactiv
influenza
vaccin
within
subgroup
healthi
preschool
children
statist
nonsignific
reduct
confirm
influenza
ci
report
base
random
control
trial
cover
influenza
season
total
size
children
current
studi
compris
children
cover
influenza
season
adequ
power
observ
statist
signific
effect
ci
ci
confirm
influenza
vaccin
group
correspond
estim
metaanalys
effect
influenzalik
ill
healthi
children
age
report
metaanalys
vari
reduct
ci
ci
children
age
year
statist
nonsignific
reduct
influenzalik
ill
ci
found
recent
random
studi
preschoolag
children
cover
singl
influenza
season
found
signific
reduct
upper
rti
lower
rti
febril
respiratori
ill
antibiot
prescript
influenza
vaccin
reduct
difficult
interpret
howev
control
group
receiv
placebo
control
vaccin
found
reduct
febril
rti
ci
group
ci
group
influenza
season
vaccin
effect
estim
appear
low
compar
report
previou
studi
definit
febril
rti
like
cover
ill
narrowli
defin
influenzalik
ill
typic
lessspecif
definit
diagnos
result
smaller
rel
reduct
obvious
even
influenza
season
larg
proport
febril
rti
children
caus
pathogen
includ
rhinovirus
human
coronavirus
parainfluenza
virus
adenovirus
particularli
season
activ
respiratori
syncyti
viru
often
cocircul
influenza
viru
nonetheless
found
reduct
aom
episod
ci
group
ci
group
indic
pivot
role
influenza
virus
condit
find
agreement
previou
nonrandom
andor
unblind
studi
preschool
children
report
reduct
aom
parenter
inactiv
subunit
influenza
vaccin
recent
metaanalysi
quasi
random
control
trial
report
reduct
aom
ci
parenter
inactiv
influenza
vaccin
among
healthi
children
age
although
pneumococc
conjug
vaccin
demonstr
highli
effect
invas
pneumococc
diseas
lesser
extent
pneumonia
appear
less
effect
mucos
infect
upper
rti
includ
aom
two
random
control
trial
pneumococc
conjug
vaccin
infant
report
reduct
aom
studi
pneumococc
conjug
vaccin
older
children
scarc
one
previou
doubleblind
random
placebocontrol
studi
nonaval
pneumococc
conjug
vaccin
children
age
month
attend
day
care
report
reduct
ci
upper
rti
ci
lower
rti
ci
aom
episod
howev
anoth
trial
follow
pneumococc
polysaccharid
vaccin
children
recurr
aom
found
benefici
effect
aom
found
overal
signific
differ
occurr
gpdiagnos
aom
episod
among
studi
group
outsid
influenza
season
data
suggest
prevent
viral
infect
preced
aom
import
variabl
although
present
studi
adequ
power
detect
rel
small
effect
reduct
data
suggest
trend
toward
increas
group
lack
effect
either
allcaus
rti
physicianattend
aom
episod
may
caus
least
part
chang
nasopharyng
carriag
vaccin
shift
serotyp
cover
vaccin
nonvaccin
serotyp
colon
bacteria
nasopharynx
although
rate
vaccin
serotyp
rti
may
decreas
replac
pathogen
may
pathogen
potenti
possibl
even
caus
increas
rate
rti
nonvaccin
serotyp
pneumococci
nasopharyng
colon
flora
replac
phenomenon
may
affect
older
children
particular
futur
studi
address
issu
depth
fact
obtain
nasopharyng
swab
influenza
pcr
test
everi
rti
episod
prevent
us
determin
total
incid
confirm
influenza
differ
studi
arm
therebi
estim
absolut
vaccin
effect
episod
swab
obtain
select
base
patient
characterist
eg
age
diseas
characterist
previous
defin
criterion
least
day
fever
accompani
least
rtiassoci
sign
symptom
sever
score
studi
arm
random
doubleblind
trial
studi
fund
netherland
organ
health
research
develop
zonmw
grant
zonmw
play
role
design
conduct
studi
collect
analysi
interpret
data
prepar
review
approv
manuscript
influenza
vaccin
provid
solvay
weesp
netherland
pneumococc
vaccin
provid
wyeth
vaccin
research
berkshir
uk
hepat
b
vaccin
provid
glaxosmithklin
bv
rixensart
belgium
jansen
wrote
first
draft
manuscript
honorarium
grant
form
payment
given
produc
manuscript
author
declar
conflict
interest
